Complete financial analysis of Quoin Pharmaceuticals, Ltd. (QNRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quoin Pharmaceuticals, Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- XXF Group Holdings Ltd (2473.HK) Income Statement Analysis – Financial Results
- Automatic Data Processing, Inc. (0HJI.L) Income Statement Analysis – Financial Results
- ReGen III Corp. (ISRJF) Income Statement Analysis – Financial Results
- Grupo Comercial Chedraui, S.A.B. de C.V. (GCHEF) Income Statement Analysis – Financial Results
- Panacea Biotec Limited (PANACEABIO.BO) Income Statement Analysis – Financial Results
Quoin Pharmaceuticals, Ltd. (QNRX)
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -280.00K | 0.00 | -280.00K | 0.00 |
| Cost of Revenue | 103.44K | 103.64K | 104.12K | 104.77K | 227.06K | 125.72K | 104.22K | 89.13K | 18.27K |
| Gross Profit | -103.44K | -103.64K | -104.12K | -104.77K | -227.06K | -405.72K | -104.22K | -369.13K | -18.27K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 144.90% | 0.00% | 131.83% | 0.00% |
| Research & Development | 3.31M | 2.67M | 1.56M | 244.16K | 45.65K | 8.26M | 5.89M | 8.26M | 1.52M |
| General & Administrative | 6.07M | 6.58M | 4.50M | 1.43M | 1.51M | 7.97M | 4.20M | 7.97M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.07M | 6.58M | 4.50M | 1.43M | 1.51M | 7.97M | 4.20M | 7.97M | 1.06M |
| Other Expenses | 0.00 | 417.31K | -14.03M | -378.33K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.38M | 9.26M | 6.06M | 1.67M | 1.56M | 16.22M | 10.10M | 16.22M | 2.58M |
| Cost & Expenses | 9.38M | 9.26M | 6.06M | 1.67M | 1.56M | 16.22M | 10.10M | 16.22M | 2.60M |
| Interest Income | 692.82K | 95.75K | 1.37K | 47.02 | 0.00 | 0.00 | 0.00 | 0.00 | 1.03K |
| Interest Expense | 0.00 | 714.08K | 1.09M | 47.02K | 412.29K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 103.44K | 103.64K | 104.12K | 104.77K | 227.06K | 125.72K | 104.22K | 89.13K | 18.27K |
| EBITDA | -9.27M | -8.74M | -21.37M | -2.01M | -1.54M | -5.47M | -7.80M | -3.91M | -2.60M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,470.36% | 0.00% | -5,470.36% | 0.00% |
| Operating Income | -9.38M | -8.85M | -20.37M | -2.05M | -1.56M | 15.32M | 10.17M | 15.32M | -2.60M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,470.36% | 0.00% | -5,470.36% | 0.00% |
| Total Other Income/Expenses | 714.32K | -123.79K | -1.09M | -425.35K | 0.00 | 2.54M | -1.06M | 237.07K | -19.30K |
| Income Before Tax | -8.66M | -9.38M | -21.46M | -2.10M | -1.56M | 15.32M | 10.17M | 15.32M | -2.62M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,470.36% | 0.00% | -5,470.36% | 0.00% |
| Income Tax Expense | 22.38K | -104.04K | -12.94M | -331.31K | 1.55M | -161.14K | -1.17M | 147.94K | -1.00 |
| Net Income | -8.69M | -9.28M | -8.52M | -1.76M | -1.56M | 15.32M | 10.17M | 15.32M | -2.62M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,470.36% | 0.00% | -5,470.36% | 0.00% |
| EPS | -9.64 | -22.97 | -322.49 | -88.10 | -440.29 | 7.10K | 5.45K | 10.08K | -2.11K |
| EPS Diluted | -9.64 | -22.97 | -322.49 | -88.10 | -440.29 | 7.10K | 5.45K | 10.08K | -2.11K |
| Weighted Avg Shares Out | 900.92K | 403.88K | 26.42K | 20.02K | 3.54K | 2.16K | 1.87K | 1.52K | 1.24K |
| Weighted Avg Shares Out (Dil) | 901.10K | 403.88K | 26.42K | 20.02K | 3.54K | 2.16K | 1.87K | 1.52K | 1.24K |
Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
Available Clinical Data from Six Subjects Demonstrates Well Define Efficacy Signals Across a Number of Study Endpoints
Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX ) Q2 2023 Results Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Chairman and Chief Executive Officer Conference Call Participants Naz Rahman -...
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results
Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 90% Today?
Quoin Pharmaceuticals (NASDAQ: QNRX ) stock is taking a massive beating on Monday as the company prepares for an ADS ratio change. According to a filing from Quoin Pharmaceuticals, the company is enacting an ADS ratio change that will switch its...
Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET
ASHBURN, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its 2022 fourth...
Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2022 Earnings Call Transcript
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX ) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants Gordon Dunn - CFO Michael Myers - CEO Conference Call Participants Aydin Huseynov - Ladenburg Thalmann James Molloy - Alliance Global Partners...
Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th
ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its third quarter 2022 financial results will be...
10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022
Penny stocks to buy according to analysts in 2022. The post 10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
7 Penny Stocks To Buy According To Top Wall Street Analysts
Penny stocks to buy according to analysts in 2022. The post 7 Penny Stocks To Buy According To Top Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Hot Penny Stocks To Watch Today As Stock Market Crash Continues
Hot penny stocks to watch today. The post Hot Penny Stocks To Watch Today As Stock Market Crash Continues appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports